Isotechnika Pharma's discovery-stage NICAM compounds are a broad platform of cyclophilin inhibitors for the treatment of cyclophilin-mediated disorders including viral, cardiac, neurological, and inflammatory diseases. The compounds are synthetically novel chemical modifications of the cyclosporine molecule which yield non-immunosuppressive high affinity cyclophilin inhibitors.  The structure-activity relationships of the compounds vis-�-vis their potency, toxicity, drug interactions, and pharmacokinetics will be discussed.

NICAMs: Development of novel cyclosporine-based cyclophilin inhibitors

246th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.